登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C24H25NO4 · HCl
化学文摘社编号:
分子量:
427.92
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
223-066-4
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
assay
≥98% (HPLC)
form
solid
color
white
solubility
H2O: ~6.6 mg/mL
originator
Johnson & Johnson
SMILES string
Cl[H].CC1=C(Oc2c(cccc2C1=O)C(=O)OCCN3CCCCC3)c4ccccc4
InChI
1S/C24H25NO4.ClH/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25;/h2,4-5,8-12H,3,6-7,13-16H2,1H3;1H
InChI key
XOEVKNFZUQEERE-UHFFFAOYSA-N
Gene Information
human ... PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144), PDE7A(5150), PDE7B(27115), PDE8A(5151), PDE8B(8622)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Flavoxate, a flavone derivative and a tertiary-amine antimuscarinic possess antispasmodic properties. It is a strong smooth muscle relaxant that selectively acts on the pelvic region and is used in the symptomatic treatment of overactive bladder (OAB) and incontinence. Post-absorption in the gastrointestinal tract, flavoxate is localized in bladder, liver, and kidney tissues. It mediates the inhibition of phosphodiesterase (PDE) in the urinary bladder. Use of flavoxate aids pain relief in inflammatory disorders of the urinary tract.
L-type Ca2+ (Cav1.2) channel inhibitor
Features and Benefits
This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate.
Zakir Shaik Mohammed et al.
British journal of clinical pharmacology, 66(5), 726-727 (2008-08-30)
Rachna Sehgal et al.
Journal of tropical pediatrics, 53(4), 259-263 (2007-05-15)
A prospective study was done in pediatric out-patient department of a tertiary care hospital to evaluate the role of urodynamics in the management of primary enuresis in the 5-14-year-old children and to compare the effectiveness of multidimensional behavioral therapy with
Yanni F Yu et al.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 8(4), 495-505 (2005-08-11)
To investigate persistence and adherence of medication treatment in chronic overactive bladder/urinary incontinence (OAB/UI) patients, and to evaluate OAB/UI-related comorbidity events associated with persistence. Pharmaceutical outcomes research with a health-care provider perspective was conducted on a California Medicaid (Medi-Cal) chronic
Saori Nishijima et al.
The Journal of urology, 173(5), 1812-1816 (2005-04-12)
We examined the mechanism involved in the inhibition of bladder activity in rats by stimulating the rostral pontine reticular formation (RPRF) using carbachol, flavoxate and propiverine, and by analysis of amino acid levels in the lumbosacral cord. A total of
Toshihisa Tomoda et al.
British journal of pharmacology, 146(1), 25-32 (2005-06-21)
The effects of flavoxate hydrochloride (Bladderon, piperidinoethyl-3-methylflavone-8-carboxylate; hereafter referred as flavoxate) on voltage-dependent nifedipine-sensitive inward Ba(2+) currents in human detrusor myocytes were investigated using a conventional whole-cell patch-clamp. Tension measurement was also performed to study the effects of flavoxate on
商品
We offers many products related to calcium channels for your research needs.
我们提供多种与钙通道相关的产品以满足您的各类研究需求。
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| F8304-50MG | 04061832961651 |
| F8304-10MG | 04061832961644 |
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持